Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and histone deacetylase inhibitors (HDIs) show promise for the treatment of cancer. However, in a number of reports they have been proven ineffective to induce cell death when applied as single agents. In this study, we show that A549 lung carcinoma cells and PC-3 prostate carcinoma cells underwent substantial apoptosis when coexposed to TRAIL and either suberoylanilide hydroxamic acid, sodium butyrate or trichostatin A. HDIs and TRAIL synergized in activation of capase-3, induction of internucleosomal DNA fragmentation and promoting mitochondrial damage. Significantly, cotreatment with minimally toxic doses of HDIs and TRAIL resulted in a marked apoptotic response in both cell lines. These data provide a rationale for a more in-depth exploration into the potential of combining TRAIL and HDIs as a valuable anticancer strategy.
Sonnemann
Jürgen
J
Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany.
Gänge
Jennifer
J
Kumar
K Saravana
KS
Müller
Cornelia
C
Bader
Peter
P
Beck
James F
JF
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins; D020148:Butyric Acid / Q000627:therapeutic use; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor / Q000187:drug effects* / Q000201:enzymology; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008562:Membrane Glycoproteins / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy; D053221:TNF-Related Apoptosis-Inducing Ligand; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*; D000077337:Vorinostat
D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D008562:Membrane Glycoproteins; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D014409:Tumor Necrosis Factor-alpha; D020148:Butyric Acid; C012589:trichostatin A; D000077337:Vorinostat; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88
14506144
Biochem Biophys Res Commun. 2004 Jan 30;314(1):186-91
14715264
Int J Cancer. 2003 Dec 20;107(6):929-40
14601052
Nature. 2000 Nov 16;408(6810):377-81
11099047
Cancer Res. 2004 Apr 1;64(7):2580-9
15059915
Blood. 2001 Nov 1;98(9):2865-8
11675364
Mol Cancer Ther. 2003 Dec;2(12):1273-84
14707268
Mol Cell. 2002 Mar;9(3):459-70
11931755
Cancer Res. 2000 Sep 15;60(18):5165-70
11016644
Cell Death Differ. 1998 Jun;5(6):480-7
10200499
Oncogene. 2004 Aug 19;23(37):6261-71
15208660
Clin Cancer Res. 2002 Mar;8(3):718-28
11895901
Cell Death Differ. 2001 Oct;8(10):1014-21
11598799
J Immunother. 2001 Nov-Dec;24(6):459-71
11759069
Oncogene. 1999 Nov 25;18(50):7016-25
10597302
Invest New Drugs. 2001;19(1):1-11
11291827
J Clin Oncol. 2003 Sep 15;21(18):3526-34
12972530
J Exp Ther Oncol. 2002 Nov-Dec;2(6):325-32
12440223
Proc Natl Acad Sci U S A. 2001 Sep 11;98 (19):10833-8
11535817
Clin Cancer Res. 2002 Apr;8(4):963-70
11948101
Cancer Chemother Pharmacol. 2002 Jul;50(1):46-52
12111111
Cancer Res. 2001 Jan 15;61(2):759-63
11212279
Nat Rev Drug Discov. 2002 Apr;1(4):287-99
12120280
J Biol Chem. 1999 Dec 3;274(49):34940-7
10574969
Cancer Res. 2001 Feb 15;61(4):1327-33
11245429
Nat Rev Cancer. 2001 Dec;1(3):194-202
11902574
Exp Cell Res. 2004 Aug 15;298(2):560-73
15265702
Cancer Res. 2000 Jun 1;60(11):3051-7
10850456
J Thorac Cardiovasc Surg. 2002 Jan;123(1):168-74
11782771
Nat Rev Cancer. 2002 Sep;2(9):647-56
12209154
J Biol Chem. 2003 Apr 4;278(14):12579-89
12556448
Lancet Oncol. 2003 Jul;4(7):407-14
12850191
Cancer Res. 1999 Sep 1;59(17):4392-9
10485488
Blood. 2002 Jun 1;99(11):4079-86
12010810
J Clin Oncol. 2002 Jun 15;20(12):2881-94
12065566
Cell. 1998 Aug 21;94(4):481-90
9727491
Clin Cancer Res. 2001 Aug;7(8):2292-300
11489804
Arch Pharm (Weinheim). 1999 Oct;332(10):353-7
10575368
Biochem Biophys Res Commun. 1999 Nov;265(1):130-3
10548502
Cell. 1997 Aug 22;90(4):595-606
9288740
Int J Mol Med. 2002 May;9(5):521-5
11956660
Cell Death Differ. 2003 Jan;10(1):66-75
12655296
J Biol Chem. 2003 May 23;278(21):18980-9
12649266
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5
14695887
Cell. 2002 Jan 25;108(2):153-64
11832206